Zydus

PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm

Retrieved on: 
Tuesday, January 4, 2022
Medical Devices, Infectious Diseases, Health, Pharmaceutical, Medical Supplies, Policy, Organic acid, COVID-19, Vaccine, U.S. FDA, Review, Therapy, Cadila Healthcare, Patient, DNA, Cancer, CE marking, US FDA, US, COVID, Degenerative disease, CEO, R & D, LinkedIn, Immunization, Inflammation, Partnership, Polio, System, Use, Certification, Technology, WHO, EUA, Injection, PQS, COVID 19, Pharmaceutical industry, PharmaJet, Enzychem, Zydus, PHARMAJET, ENZYCHEM, ZYDUS

PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila , is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila , is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.
  • The vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries.
  • Under the terms of this agreement, Zydus will transfer its manufacturing technology and provide technical assistance to Enzychem Lifesciences.
  • The vaccine is administered intradermally using the PharmaJet needle-free system, which can be deployed more readily, especially in resource-poor populations where these are urgently needed.

Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea

Retrieved on: 
Friday, November 26, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, Transfer, Policy, Patient, Plasmid, Developing country, Technology, Partnership, CHL, Cancer, Clinical trial, Inflammation, Human, KOSDAQ, Cadila Healthcare, Therapy, COVID-19, Vaccine, COVID 19, DNA, US, Organic acid, US FDA, Degenerative disease, EUA, Edwards Lifesciences, Technology transfer, COVID, Pharmaceutical industry, Enzychem, Zydus, ENZYCHEM, ZYDUS

Enzychem Lifesciences (KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zydus Group, today announced that they have entered a Manufacturing License and Technology Transfer Agreement for the worlds first plasmid DNA vaccine (ZyCoV-D).

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zydus Group, today announced that they have entered a Manufacturing License and Technology Transfer Agreement for the worlds first plasmid DNA vaccine (ZyCoV-D).
  • Under the terms of this agreement, Zydus shall transfer its manufacturing technology and provide technical assistance to Enzychem.
  • Both CHL and Enzychem believe that this partnership will lead to estimated manufacturing of 80 million or more doses of the plasmid DNA vaccine in 2022.
  • Mr. Ki Young Sohn, Chairman of Enzychem Lifesciences said: Today marks an important milestone for our vaccine consortium as we embark on the manufacturing of the worlds first- in-class DNA vaccine for humans.

PharmaJet Presents How to Improve Vaccine Performance with Needle-free Delivery at Vaccine World Asia Congress

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Cadila Healthcare, Rabies, WHO, Injector, Vaccine, MBA, U.S. FDA, PQS, CE marking, Use, COVID-19, Research, Injection, Polio, Needle, LinkedIn, Solution, Therapy, R & D, Certification, Review, Vaccination, DNA, Feedback, MS, Pharmaceutical industry, PharmaJet, Zydus, PHARMAJET, ZYDUS

PharmaJet , the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17.
  • The presentation, entitled Improving Vaccine Performance with Needle-free Delivery, is being presented by Paul LaBarre, MS, MBA, Vice President, Global Business Development.
  • The vaccine will be delivered exclusively with the PharmaJet Tropis Intradermal Needle-free Injection System.
  • PharmaJets mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market.